Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/21/2025

Monitoring Testosterone Gel Therapy

Introduction to Monitoring Principles

  • Transdermal testosterone preparations can be measured at any time of day without holding the dose, as recommended by the Endocrine Society, due to the variability in gel absorption 1, 2, 3, 4, 6, 7
  • This flexibility differs from injectable testosterone, which requires specific timing, midway between injections, as suggested by clinical guidelines 1, 2, 3, 4, 6

Key Monitoring Considerations

  • Peak testosterone levels occur approximately 6-8 hours after gel application, although this can vary, according to the American Urological Association 1, 4
  • Testosterone concentrations vary substantially with gel use, in a non-predictable manner, highlighting the need for individualized monitoring, as noted by the American College of Endocrinology 1, 2, 3, 4, 6, 7
  • Serum testosterone reaches steady-state within the first 24 hours of gel application, and levels remain relatively stable day-to-day compared to injectable formulations, as observed in clinical studies 1, 2, 4, 5, 6, 7

Practical Monitoring Approaches

  • Draw testosterone levels 2-3 months after treatment initiation or any dose change, at any convenient time, as recommended by the Endocrine Society 1, 2, 3, 4, 5, 6, 7
  • Target mid-normal range (500-600 ng/dL) for therapeutic levels, according to clinical guidelines 1, 3, 4
  • Once stable levels are confirmed, monitor every 6-12 months, continuing to draw at any convenient time, as suggested by the American College of Endocrinology 1, 2, 3, 4, 5, 6, 7

Critical Considerations for Monitoring

  • Gel absorption is inherently variable and unpredictable between patients, making strict timing unnecessary, as noted by the American Urological Association 1, 2, 3, 4, 6, 7
  • Morning draws (8-10 AM) are only required for diagnostic purposes before starting therapy, not for monitoring, according to the Endocrine Society 1, 2, 4, 5